VIP Dosage Guide, Benefits & Side Effects

Lyophilized (freeze-dried) VIP is generally reported to remain stable for 12-24 months when stored frozen (around -20°C), kept dry and protected from light, prior to reconstitution. Once reconstituted (commonly with bacteriostatic water for injectable forms, or formulated into a nasal spray by a compounding pharmacy), stability drops substantially: refrigerated (2-8°C) reconstituted solution is commonly cited as usable for about 28 days, though bioactivity can begin declining within days, and exposure to room temperature for extended periods degrades it much faster. As with any peptide, exact stability depends on the specific formulation, concentration, and buffer used, so manufacturer or pharmacy-specific guidance should be followed rather than generic figures.

VIP itself has a very short plasma half-life, on the order of a few minutes, because it is rapidly broken down by peptidases in circulation. Despite this, receptor activation can trigger downstream signaling cascades that produce effects lasting several hours after a single dose. In the context of a multi-week or multi-month CIRS protocol, meaningful changes in inflammatory lab markers (e.g., TGF-β1, MMP-9, C4a, VEGF) are typically assessed after weeks of consistent dosing rather than after a single administration.

VIP itself is not an FDA-approved drug for self-administered human use; it is listed by the FDA as a Category 1 bulk drug substance under evaluation for use in 503A compounding, meaning licensed compounding pharmacies may prepare it (e.g., as a nasal spray) with a valid prescription in certain circumstances, subject to regulatory change. A related synthetic form, aviptadil, has been studied as an investigational drug in clinical trials but is likewise not broadly FDA-approved. VIP is also widely sold by research chemical suppliers labeled 'for research use only, not for human consumption'; such products fall outside FDA-approved drug status and are not intended for self-administration. Because regulations and enforcement can change and vary by country, anyone considering VIP for a health condition should consult a licensed prescriber rather than relying on research-grade product or online protocols.

In practice, VIP is most often discussed as a standalone final step in the Shoemaker CIRS protocol rather than something combined with other peptides, precisely because it is meant to be introduced only after other interventions (binders, hormone correction, MARCoNS treatment) have already been completed. Some research and clinical discussions have paired VIP with treatments for pulmonary or inflammatory conditions in supervised settings. There is limited public data on combining VIP with other commonly used research peptides (e.g., BPC-157, TB-500), and any such combinations would carry unknown interaction risks, particularly given VIP's cardiovascular effects. Decisions about combining VIP with other compounds should be made with a qualified healthcare provider rather than based on anecdotal stacking reports.